Navigation Links
AviaraDx Presents at 2007 BIOCOM Investor Conference
Date:10/5/2007

Newly formed molecular diagnostic company launches two oncology tests

SAN DIEGO, Oct. 5 /PRNewswire/ -- AviaraDx, Inc., announced today that the company is scheduled to provide a corporate overview of its molecular diagnostic test offerings and development programs at the 2007 BIOCOM Investor Conference. The presentation is scheduled for Thursday, November 1st, at 2:30 p.m. in the Rancho Santa Fe ballroom of the San Diego Marriott Del Mar Hotel, 11966 El Camino Real, San Diego, CA 92130.

About AviaraDx, Inc.

AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will provide information critical to predict treatment response to a given therapeutic regimen. AviaraDx offers diagnostic tests to qualified physicians or laboratories through its CAP-certified CLIA laboratory service operations. The company's first diagnostic test offerings are based on its proprietary technologies for the molecular classification of metastatic cancer, CancerTYPE ID(TM), and its H/I(TM) (HOXB13/IL17BR) test to assess risk of recurrence and response to endocrine therapy in certain breast cancer patients.

CONTACT:

Antonius Schuh, Ph.D.

Chief Executive Officer

+1 (760) 579 0500

aschuh@aviaradx.com


'/>"/>
SOURCE AviaraDx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
8. International Conference On Malaria - Laveran To Genomics
9. African Conference to Combat AIDS
10. International conference on Ayurveda to be held on Kerala
11. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today welcomed the announcement by OPKO Health ... Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... its industry-defining contract lifecycle management solution, as well as announced the date of ... the speed and ease of contract management tasks as well as enhancements to ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... announce the development of it’s new program “Designing Secure Healthcare Systems” This ... engineers and technology leaders from healthcare organizations with access to the tactics, techniques ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... has passed since a research institute here developed the first ... be no takers for its formula or even its doses, ... ,The High Security Animal Disease Laboratory (HSADL) here, which developed ... of the vaccine, each costing 27 paise. But no drug ...
... often than we think, but it is also more ... early//. Children and adolescents should be monitored carefully because ... often has its roots in childhood. ,Kidney disease ... only when it’s far too late to stop the ...
... who devote more time to physical activity have a ... next 15 years, according to new research// . ... physical activity is actually causally related to hypertension,” said ... an epidemiologist at the University of Minnesota in Minneapolis, ...
... to inappropriate treatment for their children's life-threatening condition. A ... research. ,Rishi Mediratta's data – interviews, stool ... proportion” of the mothers in one Ethiopian community did ... to either prevent diarrheal disease or manage it. ...
... enjoy life outside. An extra hour to stay up late. And ... do when the clock jukes and jives with our circadian rhythms, ... enough for adults, who understand the concept. What about kids, who ... sun’s still up, how can it be bedtime? ,Dr. ...
... was conducted in 50 countries on World Kidney day ... and the International Federation of Kidney Foundations. ... to emphasize to the masses the importance of kidneys ... common and serious but certainly capable of treatment. ...
Cached Medicine News:Health News:No Takers for India's First Bird Flu Vaccine 2Health News:Kidney Disease In Children: Common but Treatable 2Health News:Physical Activity Reduces Hypertension Risk in Young Adults 2Health News:Mothers in African Study Undereducated on Diarrhea 2Health News:Mothers in African Study Undereducated on Diarrhea 3Health News:Use Daylight-saving Change to Practice Healthy Sleep Habits 2
(Date:8/3/2015)... , August 3, 2015 ... announced today that it has acquired ... Inc. for $300 million. With the acquisition, Shire ... drops combining 0.6% povidone iodine (PVP-I) and 0.1% ... treatment of infectious conjunctivitis, an ocular surface condition ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Calif., Jan. 4, 2011 Intarcia Therapeutics, Inc. today ... will present at the 29th Annual JP Morgan Healthcare ... 2011 at the Westin St. Francis Hotel in San ... About Intarcia Intarcia Therapeutics, ...
... Pa., Jan. 4, 2011 Owner and medical director of ... her practice and is now offering Pixel Perfect™ ... CO2 laser from Alma Lasers. "I,m very ... Cirillo-Hyland said. "As a long time provider of aesthetic laser ...
Cached Medicine Technology:Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference 2Philadelphia's Victoria A. Cirillo-Hyland, M.D. Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2
Galilean Loupes...
... Over 40 cm field-of-view enables high-quality ... system with scalable 32-channel architecture. New powerful ... 3.0T imaging up to 80 mT/m ... SAR management to fully exploit the power ...
... fusion system represents a breakthrough for patients ... spine. The system gathers bone during decompression, ... of bone into the implant's chamber produces ... harvest from the iliac crest. The BAK/C ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: